Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $985000.0.

  • Whitehawk Therapeutics' Change in Accured Expenses rose 11615.02% to $985000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$156000.0, marking a year-over-year increase of 9718.92%. This contributed to the annual value of -$9.8 million for FY2024, which is 730378.79% down from last year.
  • As of Q3 2025, Whitehawk Therapeutics' Change in Accured Expenses stood at $985000.0, which was up 11615.02% from -$2.7 million recorded in Q2 2025.
  • Whitehawk Therapeutics' Change in Accured Expenses' 5-year high stood at $5.0 million during Q3 2022, with a 5-year trough of -$9.8 million in Q3 2021.
  • For the 5-year period, Whitehawk Therapeutics' Change in Accured Expenses averaged around -$832263.2, with its median value being $592000.0 (2021).
  • Data for Whitehawk Therapeutics' Change in Accured Expenses shows a peak YoY increase of 74064.52% (in 2022) and a maximum YoY decrease of 79746.62% (in 2022) over the last 5 years.
  • Whitehawk Therapeutics' Change in Accured Expenses (Quarter) stood at $155000.0 in 2021, then surged by 740.65% to $1.3 million in 2022, then soared by 269.53% to $4.8 million in 2023, then tumbled by 87.71% to $592000.0 in 2024, then surged by 66.39% to $985000.0 in 2025.
  • Its Change in Accured Expenses stands at $985000.0 for Q3 2025, versus -$2.7 million for Q2 2025 and $975000.0 for Q1 2025.